30-60-90 day plan for clinical research coordinators
On this page
- What makes a clinical research coordinator's first 90 days different?
- What does the 30-60-90 day plan look like?
- Which regulations does a new clinical research coordinator check first?
- Which numbers should a new coordinator track?
- What does "on track" look like at day 30, 60 and 90?
- A filled example
- How should the hiring manager use this plan in the final interview?
- What should the PI and research manager ask at the check-ins?
- What the site owes a new clinical research coordinator
- Common mistakes
- Adapting the plan
- Questions people ask
A 30-60-90 day plan for a new clinical research coordinator should spend the first 30 days on training, delegation, shadowing and a regulatory binder audit, with no study task done before the coordinator is trained and on the delegation log; days 31-60 running study visits, consent, data entry and query resolution independently on two or three studies; and days 61-90 owning a protocol end to end, including implementing an amendment and submitting a continuing review. As of November 2026, the work sits under FDA's rules on informed consent (21 CFR 50), IRBs (21 CFR 56) and investigators (21 CFR 312 or 812), the HIPAA research rules, and FDA's E6(R3) Good Clinical Practice guidance, final since September 2025.
This plan is for the principal investigator, research manager or site director hiring a coordinator at an academic medical center, hospital research office or independent research site. The interview loop for the role, including a protocol deviation scenario and FDA debarment checks, is in the interview guide for research roles. A clinical laboratory's CLIA duties are a different job, covered in the 30-60-90 day plan for lab managers.
What makes a clinical research coordinator's first 90 days different?
Most new hires can learn by doing. A coordinator cannot do a study task until the principal investigator has delegated it and the training is documented, because the delegation log and training records are part of what a monitor, an auditor or an FDA investigator reviews. The first month therefore looks slow from outside: training modules, signatures, shadowed visits. That slowness is the control.
The second difference is that errors are found late. A consent signed on a superseded version, a visit done outside its window or a lab drawn in the wrong tube is often discovered weeks later at a monitoring visit, when it can only be reported, not prevented. The plan puts the checks that prevent those errors (version control, visit-window tracking, same-day source documents) into the coordinator's routine from the first independent visit.
What does the 30-60-90 day plan look like?
30-60-90 day plan — [Name], Clinical Research Coordinator, [site / department]
Principal investigator: [name] Reports to: [research manager] Start: [date]
Studies: [N] active ([phase / sponsor or investigator-initiated / drug or device])
IRB: [central / local] Systems: [EDC], [IRT], [eRegulatory], [CTMS], [EHR]
DAYS 1-30 — Train, get delegated, learn the studies
Goals:
- Complete required training: GCP, human subjects protection, HIPAA,
site SOPs, and specimen shipping if the role ships samples
- Get added to each study's delegation log, with training documented,
before performing any study task
- Shadow [6] consent discussions and [10] study visits
- Read each protocol's schedule of assessments and visit windows
- Audit each regulatory binder: current IRB approvals and consent
versions, Form FDA 1572, CVs, licenses, training logs, lab documents
- Meet the PI, subinvestigators, pharmacy, lab, IRB office and each
sponsor's monitor
Deliverables by day 30:
- Study tracker: status, enrollment vs target, upcoming visits and
windows, open queries, IRB expiry dates, current consent version
- Binder gap list with owners and dates
Check-in: day 30
DAYS 31-60 — Run visits independently on [2-3] studies
Goals:
- Consent participants under PI oversight on the current version;
document the process in the source the same day
- Run visits inside windows; source documents completed same day
- Enter data and answer queries inside each sponsor's timeline
- Keep screening and enrollment logs current
- Prepare for and host a monitoring visit as primary coordinator
- Walk the adverse event and serious adverse event workflow with the
PI, including evenings and weekends
Deliverables by day 60:
- Visits and data entry on owned studies within windows and timelines
- Monitoring findings from the visit closed or scheduled
Check-in: day 60
DAYS 61-90 — Own a protocol
Goals:
- Implement an amendment: IRB approval, staff training, re-consent
where required, version control in every location
- Submit a continuing review or annual report ahead of expiry
- Agree a recruitment plan with the PI for the slowest-enrolling study
- Support start-up of a new study: feasibility, budget questions,
site initiation visit preparation
Deliverables by day 90:
- Amendment implemented with no superseded forms in use
- Recruitment plan with weekly numbers, and a back-up coordinator
trained on the owned protocol
Check-in: day 90 — full review with the PINumbers in brackets are examples. Size them to the portfolio, the phase of the studies and how much the coordinator has done before.
Which regulations does a new clinical research coordinator check first?
The federal rules below, as they read in November 2026, are the ones a coordinator's daily work touches most. They are not legal advice; the protocol, the sponsor's contract, the IRB's policies, the site's SOPs and state law add requirements.
| Area | What the rule says | What the coordinator checks |
|---|---|---|
| Informed consent (21 CFR 50.27(a); 312.62(b)) | Consent is documented on a written, IRB-approved form signed and dated by the participant or their legally authorized representative at the time of consent, and a copy is given to the signer; each case history must show consent was obtained before participation | The current version is the only one available, signatures and dates are complete, the copy was given, and the source note describes the consent process |
| IRB oversight (21 CFR 56.109(f); 312.66; 45 CFR 46.109(f)) | FDA-regulated research gets continuing review at least once a year; the investigator promptly reports changes and unanticipated problems and makes no changes without IRB approval, except to remove an apparent immediate hazard. Under the Common Rule, continuing review is not required for research eligible for expedited review unless the IRB decides otherwise | Approval expiry dates on the tracker, and amendments used only after approval |
| Safety reporting (21 CFR 312.64(b)) | The investigator must immediately report any serious adverse event to the sponsor, whether or not considered drug related, with an assessment of causality; nonserious events follow the protocol's timetable | Who is reachable out of hours, and the protocol's own clock and forms |
| Drug accountability and records (21 CFR 312.62) | Records of drug disposition (dates, quantity, use by participants) and accurate case histories; retention for 2 years after approval of a marketing application for the indication, or 2 years after the investigation is discontinued and FDA notified | Accountability logs agree with pharmacy and the IRT system; the contract's retention period, which is often longer |
| Investigator statement (21 CFR 312.53(c)) | Before an investigator starts, the sponsor obtains a signed Form FDA 1572 naming the sites, clinical labs, the IRB and the subinvestigators | The 1572 matches who actually works on the study and which lab runs the samples |
| Electronic records (21 CFR 11.1) | Part 11 sets the criteria for electronic records and signatures to be trustworthy and equivalent to paper | Own credentials for every system, never shared logins; certified copies when paper source is scanned |
| Health information for research (45 CFR 164.508; 164.512(i)) | Using protected health information for research needs the person's authorization, unless an IRB or privacy board approves a waiver or alteration | A signed authorization or a documented waiver before pre-screening medical records |
| Registration and results (42 CFR 11.24; 11.44) | For applicable clinical trials, the responsible party registers on ClinicalTrials.gov within 21 calendar days after the first participant is enrolled and submits results within 1 year after the primary completion date | For investigator-initiated trials where the PI is the responsible party, both dates on the tracker |
| Good Clinical Practice (FDA: E6(R3) guidance; NIH NOT-OD-16-148) | FDA issued ICH E6(R3) as final guidance in September 2025; it states FDA's current thinking rather than binding rules. NIH expects investigators and staff on NIH-funded clinical trials to be trained in GCP and to refresh it at least every three years | Training certificates in the binder, with refresh dates |
| Specimen shipping (49 CFR 173.199(e)) | Each person who offers or transports a Category B infectious substance must know the requirements of the section | Shipping training is documented before the first shipment, alongside the courier's and sponsor's lab manual requirements |
Which numbers should a new coordinator track?
The measures below are examples. Sponsors set some timelines in the contract, such as data entry after a visit; use those, not invented targets.
| Measure (examples only) | What it shows |
|---|---|
| Enrollment against target, per study; screen failures by reason | Whether recruitment works and where eligibility is lost |
| Visits completed inside protocol windows | Scheduling discipline |
| Days from visit to data entry; queries open past the sponsor's timeline | Data quality and workload |
| Protocol deviations by type (consent version, missed procedure, out of window) | Which control is failing |
| Consent documentation errors found at monitoring | The most serious recurring risk |
| Binder items missing or expired (licenses, CVs, training, lab documents) | Inspection readiness |
What does "on track" look like at day 30, 60 and 90?
| Checkpoint | On track | Worth a direct conversation |
|---|---|---|
| Day 30 | Training complete and filed; on every delegation log before any task; tracker and binder gap list done | Study tasks done before delegation; tracker kept in memory or scattered emails |
| Day 60 | Visits inside windows; source completed the same day; data and queries inside sponsor timelines; a monitoring visit hosted | Source written up days later; query backlog growing; deviations found only by the monitor |
| Day 90 | Amendment implemented with clean version control; continuing review submitted early; a recruitment plan with numbers | Superseded consent forms still in clinic drawers; IRB expiry discovered the week it happens |
A filled example
Clinical research coordinator: Kayla Nguyen (invented), new coordinator in a community hospital's oncology research office with four industry-sponsored drug trials and one investigator-initiated study. All details are examples.
Day 30: Her binder audit found two subinvestigators' license copies expired and one Form FDA 1572 that did not list a fellow who had joined the team. Her consent check found one participant consented on the previous version after an amendment, which the PI reported to the IRB as a deviation under the IRB's policy. One study had a query backlog of more than 60 items.
Day 60: She ran visits on two studies, entered data inside the sponsor's timeline, cleared the backlog and hosted her first monitoring visit, which closed with two minor findings. Superseded consent forms were removed from the clinic, and a single current-version folder replaced the printed stacks.
Day 90: She implemented an amendment: IRB approval, training for the team, re-consent of active participants at their next visits and a version log. The continuing review for the investigator-initiated study went in weeks before expiry, and a second coordinator was trained as her back-up.
How should the hiring manager use this plan in the final interview?
Give every finalist the same brief: the portfolio, the systems and one de-identified problem, such as a query backlog or a slow-enrolling study. Score the plans with the rubric in how to evaluate a 30-60-90 day plan in an interview; the clinical research coordinator screening questions cover the earlier phone screen, including credentials and safety reporting. Questions that test this plan:
- "A participant can only come in two days outside the visit window. What do you do?"
- "You notice that last week's consent was signed on the previous version. Walk me through the next steps."
- "The monitor leaves 40 open queries on your study. How do you plan the week?"
- "A participant calls on Saturday to say they were admitted to hospital. What happens next, and by when?"
Strong candidates name the PI's role at each step, check the protocol and the IRB's policy before answering, and treat documentation as part of the care of the participant rather than paperwork.
What should the PI and research manager ask at the check-ins?
- Day 30: Which tasks are you delegated on each study? What did the binder audit find, and who fixes each item?
- Day 60: Which visits fell outside a window, and why? What did the monitor find?
- Day 90: Where does every current consent version live? Which IRB dates fall in the next quarter? What would speed up enrollment?
What the site owes a new clinical research coordinator
- Training time and access to each sponsor's systems before the first independent visit.
- The site's SOPs, the delegation log process and a named back-up coordinator.
- A standing weekly meeting with the PI, and a clear out-of-hours contact for safety events.
- Support for a credential once eligible, such as ACRP's Certified Clinical Research Coordinator or SOCRA's Certified Clinical Research Professional; as of November 2026 both are awarded by exam after eligibility requirements are met.
Common mistakes
- Working before delegation. A task done before the PI signs the log is a finding, however well it was done.
- Version drift after an amendment. Old consent forms in a drawer or a shared drive are the usual cause of consent deviations.
- Late source documents. Notes written days after the visit are harder to defend and miss details.
- Treating queries as clerical. A query is a question about data quality; the answer belongs in the source, not only in the EDC.
- Losing track of IRB dates. Submit continuing reviews well ahead of expiry; the IRB's policy says what must pause if approval lapses.
Adapting the plan
- Device studies: replace 21 CFR 312 with 21 CFR 812; as of November 2026, under 812.150(a)(1) an investigator reports an unanticipated adverse device effect to the sponsor and the IRB as soon as possible and within 10 working days.
- Investigator-initiated trials: add the ClinicalTrials.gov dates, the IND or IDE sponsor duties the PI holds, and the data management plan to month three.
- Independent research sites: weight recruitment, screening logs and visit capacity more heavily, since enrollment drives the site's revenue.
- Federally funded studies that are not FDA-regulated: the Common Rule (45 CFR 46) sets IRB requirements; drop the FDA-specific rows that do not apply.
Coordinators handle a lot of protected health information, so the 30-60-90 day plan for privacy officers is useful background on how the site's HIPAA program is meant to work.
Questions people ask
What should a new clinical research coordinator do in the first 30 days?
Finish the site's required training (Good Clinical Practice, human subjects protection, HIPAA and specimen shipping if relevant), get added to each study's delegation log before doing any study task, shadow consent and study visits, read each protocol's schedule of assessments, audit the regulatory binders, and build a tracker of every study's status, enrollment, visit windows, open queries and IRB dates.
How fast must a clinical research coordinator report a serious adverse event?
For drug studies under an IND, 21 CFR 312.64(b) says the investigator must immediately report any serious adverse event to the sponsor, whether or not it is considered drug related, and the protocol sets the exact clock and form. For device studies, 21 CFR 812.150(a)(1) requires unanticipated adverse device effects to be reported to the sponsor and the IRB as soon as possible and within 10 working days. These rules are current as of November 2026; follow the protocol and the site's SOPs.
How long must a research site keep clinical trial records?
As of November 2026, under 21 CFR 312.62(c), an investigator keeps the records for 2 years after a marketing application is approved for the indication studied, or, if no application is filed or approved, until 2 years after the investigation is discontinued and FDA is notified. Sponsor contracts, institutional policies and other laws often require longer, so the coordinator checks the contract before anything is archived or destroyed.
Which certifications do clinical research coordinators earn?
As of November 2026, two coordinator credentials are ACRP's Certified Clinical Research Coordinator (CCRC), which recognizes experience coordinating trials under a principal investigator and requires passing an exam, and SOCRA's Certified Clinical Research Professional (CCRP). Neither is required by FDA regulations; whether a site asks for one is the employer's choice, and both have experience requirements before the exam.